» Articles » PMID: 20404570

MiR-129 Regulates Cell Proliferation by Downregulating Cdk6 Expression

Overview
Journal Cell Cycle
Specialty Cell Biology
Date 2010 Apr 21
PMID 20404570
Citations 89
Authors
Affiliations
Soon will be listed here.
Abstract

Reduced expression of miR-129 has been reported in multiple tumor cell lines and in primary tumors including medulloblastoma, undifferentiated gastric cancers, lung adenocarcinoma, endometrial cancer and colorectal carcinoma. There is also recent evidence of an anti-proliferative activity of miR-129 in tumor cell lines. Still, little is known about how miR-129 regulates cell proliferation. Here we found that lentiviral-mediated overexpression of miR-129 in mouse lung epithelial cells (E10 cells) results in significant G(1) phase arrest that eventually leads to cell death. miR-129 induce G(1) phase arrest in multiple human lung adenocarcinoma cell lines, suggesting miR-129 targeting of G(1)/S phase-specific regulators. Interestingly, we show that Cdk6, a kinase involved in G(1)-S transition, is a direct target of miR-129. We also found the downregulation of three other cell cycle-related novel targets of miR-129, including Erk1, Erk2 and protein kinase C epsilon (Prkce). We further show that among these targets, only Cdk6 is functionally relevant. Restoring expression of Cdk6, but not Prkce partially rescues the cell growth arrest and cell death phenotype that results from miR-129 overexpression. Together, our data indicate that miR-129 plays an important role in regulating cell proliferation by downregulation of Cdk6.

Citing Articles

Hydroquinidine displays a significant anticarcinogenic activity in breast and ovarian cancer cells via inhibiting cell-cycle and stimulating apoptosis.

Yavuz M, Sahin B, Baykal A, Demircan T Turk J Biol. 2023; 47(1):44-60.

PMID: 37529110 PMC: 10388048. DOI: 10.55730/1300-0152.2640.


Development of a 5-FU modified miR-129 mimic as a therapeutic for non-small cell lung cancer.

Hwang G, Yuen J, Fesler A, Farley H, Haley J, Ju J Mol Ther Oncolytics. 2023; 28:277-292.

PMID: 36911069 PMC: 9995506. DOI: 10.1016/j.omto.2023.02.007.


Screening and identification of miRNAs regulating genes of .

Zhang C, Zhang S, Liu M, Wang Y, Wang D, Xu S PeerJ. 2022; 10:e14300.

PMID: 36312751 PMC: 9610670. DOI: 10.7717/peerj.14300.


Cell cycle associated miRNAs as target and therapeutics in lung cancer treatment.

Fariha A, Hami I, Tonmoy M, Akter S, Al Reza H, Bahadur N Heliyon. 2022; 8(10):e11081.

PMID: 36303933 PMC: 9593298. DOI: 10.1016/j.heliyon.2022.e11081.


Development of 5-FU-modified tumor suppressor microRNAs as a platform for novel microRNA-based cancer therapeutics.

Yuen J, Fesler A, Hwang G, Chen L, Ju J Mol Ther. 2022; 30(11):3450-3461.

PMID: 35933584 PMC: 9637772. DOI: 10.1016/j.ymthe.2022.07.015.